Brightflow Raises €16.5 Million in Series A Funding Round

Brightflow raises millions. The company specializing in the field of long-term percutaneous mechanical circulatory support to treat patients with end-stage heart failure has announced the completion of an oversubscribed €16.5 million Series A financing round.

Brightflow round was led by new investors Vives Partners, Majycc Innovation Santé – UI Investissement, BNP Paribas Development and international business angels, with continued participation from GO Capital’s partnership with Karista. The proceeds will be used to fund the company’s key strategic initiatives until early 2026.

The goal of Brightflow is to develop long-term, fully percutaneous right ventricular mechanical circulatory support to treat end-stage heart failure in patients with severe right ventricular dysfunction.

Right ventricular dysfunction affects three million patients in Europe and the United States. It can be an isolated condition or associated with left ventricular dysfunction. Right ventricular dysfunction significantly affects the patient, with an average survival rate of two to three years. Mechanical surgical support is rarely implemented because the perioperative mortality rate varies between 30% and 50%.

Brightflow hired a new CEO at the end of August

“This funding is a testament to the strength of our technology and our promise to create the first long-term blood pump that can be safely and effectively delivered without open-heart surgery,” said Sophie Humbert, CEO of Brightflow.

Humbert was appointed CEO of the French company at the end of August. She will be responsible for defining the appropriate strategy to make the implantable system ready for patient use. Her mission includes, among other responsibilities, structuring the company, creating a solid team and leading it.

The executive holds a PhD in Industrial Pharmacy from the Claude Bernard University, Lyon 1 (France) and in Pharmaceutical Sciences from the University of Geneva (Switzerland). She holds a Master’s degree in Administration from EM Lyon, also in France. The executive comes to Brightflow with a long track record in the commercialization of innovative products.

Last March, she left her position as COO of LimFlow, a company focused on the treatment of chronic ischemia that Inari Medical will buy at the end of 2023 for $415 million.

__

(Featured image by jesse orrico via Unsplash)

DISCLAIMER: This article was written by a third party contributor and does not reflect the opinion of Born2Invest, its management, staff or its associates. Please review our disclaimer for more information.

This article may include forward-looking statements. These forward-looking statements generally are identified by the words “believe,” “project,” “estimate,” “become,” “plan,” “will,” and similar expressions. These forward-looking statements involve known and unknown risks as well as uncertainties, including those discussed in the following cautionary statements and elsewhere in this article and on this site. Although the Company may believe that its expectations are based on reasonable assumptions, the actual results that the Company may achieve may differ materially from any forward-looking statements, which reflect the opinions of the management of the Company only as of the date hereof. Additionally, please make sure to read these important disclosures.

First published in PlantaDoce. A third-party contributor translated and adapted the article from the original. In case of discrepancy, the original will prevail.

Although we made reasonable efforts to provide accurate translations, some parts may be incorrect. Born2Invest assumes no responsibility for errors, omissions or ambiguities in the translations provided on this website. Any person or entity relying on translated content does so at their own risk. Born2Invest is not responsible for losses caused by such reliance on the accuracy or reliability of translated information. If you wish to report an error or inaccuracy in the translation, we encourage you to contact us